Published in Neurology on March 01, 1994
Sensory Attention Focused Exercise in Parkinson's Disease | NCT01246700
A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord (2013) 1.94
Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry (2003) 1.70
Delaying mobility disability in people with Parkinson disease using a sensorimotor agility exercise program. Phys Ther (2009) 1.36
Striding out with Parkinson disease: evidence-based physical therapy for gait disorders. Phys Ther (2009) 1.31
Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. JAMA Neurol (2013) 1.30
Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration. Eur J Neurosci (2011) 1.24
Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease. Mov Disord (2010) 1.22
Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther (2012) 1.13
Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [¹⁸F]fallypride. Mov Disord (2010) 1.03
Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res (2010) 0.92
The Efficacy of Exercise Programs for Parkinson's Disease: Tai Chi versus Combined Exercise. J Clin Neurol (2013) 0.88
Exercise and motor training in people with Parkinson's disease: a systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials. Parkinsons Dis (2011) 0.86
Parkinson's disease. Diagnosis and treatment. West J Med (1996) 0.84
Robot-assisted walking training for individuals with Parkinson's disease: a pilot randomized controlled trial. BMC Neurol (2013) 0.81
Effects of home exercise on physical function and activity in home care patients with Parkinson's disease. J Phys Ther Sci (2014) 0.81
Effect of muscle vibration on spatiotemporal gait parameters in patients with Parkinson's disease. J Phys Ther Sci (2014) 0.80
An evidence-based exercise regimen for patients with mild to moderate Parkinson's disease. Brain Sci (2013) 0.79
Therapeutic effects of intensive inpatient rehabilitation in advanced Parkinson's disease. Neurol Clin Neurosci (2016) 0.78
Virtual reality feedback cues for improvement of gait in patients with Parkinson's disease. Tremor Other Hyperkinet Mov (N Y) (2014) 0.78
Effectiveness of an inpatient movement disorders program for patients with atypical parkinsonism. Parkinsons Dis (2011) 0.77
An android-based heart monitoring system for the elderly and for patients with heart disease. Int J Telemed Appl (2014) 0.77
Physical therapy in Parkinson's disease. Neurology (1995) 0.75
The Effects of Physical Activity in Parkinson's Disease: A Review. J Parkinsons Dis (2016) 0.75
Robot-assisted gait training versus treadmill training in patients with Parkinson's disease: a kinematic evaluation with gait profile score. Funct Neurol (2016) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Core assessment program for intracerebral transplantations (CAPIT). Mov Disord (1992) 5.51
Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med (1996) 3.48
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord (1994) 2.77
Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol (2001) 2.51
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med (1999) 2.00
Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology (1998) 1.95
FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology (2007) 1.80
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Risk factors for nursing home placement in advanced Parkinson's disease. Neurology (1993) 1.76
Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci (2000) 1.75
Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol (1999) 1.75
Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol (2013) 1.61
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology (1998) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology (2002) 1.54
Risk factors for progression in Parkinson's disease. Neurology (1988) 1.49
Animal model of posthypoxic myoclonus: effects of serotonergic antagonists. Neurology (1999) 1.47
Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology (1995) 1.46
Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use. Mov Disord (1996) 1.46
Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section. Mov Disord (1998) 1.42
New lessons from old drugs: amantadine and Parkinson's disease. Neurology (1998) 1.39
Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry (2000) 1.36
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology (1997) 1.32
Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease. Mov Disord (1997) 1.32
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology (2004) 1.28
Tardive dyskinesia: review and update. Am J Psychiatry (1980) 1.25
Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord (1997) 1.23
Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology (2003) 1.19
"On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord (2000) 1.19
Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology (1992) 1.17
Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology (1992) 1.16
Intact mirror-tracing and impaired rotary-pursuit skill learning in patients with Huntington's disease: evidence for dissociable memory systems in skill learning. Neuropsychology (1997) 1.15
Tardive dyskinesia: pharmacology and clinical implications. Clin Neuropharmacol (1982) 1.15
Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol (1989) 1.14
Autonomic dysfunction in Parkinson's disease. Neurology (1986) 1.13
Romberg's sign: development, adoption, and adaptation in the 19th century. Neurology (2000) 1.13
Objective changes in motor function during placebo treatment in PD. Neurology (2000) 1.12
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology (2003) 1.12
Cessation of driving and unsafe motor vehicle operation by dementia patients. Arch Intern Med (1991) 1.10
Environmental factors and Parkinson's disease: a case-control study in China. Neurology (1989) 1.10
Adult tics in Gilles de la Tourette's syndrome: description and risk factors. Neurology (1992) 1.09
Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol (1995) 1.06
Working and strategic memory deficits in schizophrenia. Neuropsychology (1998) 1.05
Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology (2004) 1.05
Primary writing tremor: a selective action tremor. Neurology (1982) 1.05
Changes in parahippocampal white matter integrity in amnestic mild cognitive impairment: a diffusion tensor imaging study. Behav Neurol (2009) 1.04
Age-associated reduction of asymmetry in prefrontal function and preservation of conceptual repetition priming. Neuroimage (2008) 1.02
Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord (1999) 1.02
Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology (1999) 1.00
A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch Neurol (1982) 1.00
Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord (2000) 0.99
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol (1998) 0.98
Weekly drug holiday in Parkinson disease. Neurology (1981) 0.98
Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry (1982) 0.98
Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology (1998) 0.97
Historical underpinnings of the term essential tremor in the late 19th century. Neurology (2008) 0.96
Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease. Arch Neurol (2001) 0.95
Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol (1998) 0.95
Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients: dose-response study and correlations with plasma levels. Neurology (1996) 0.95
Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology (1992) 0.95
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology (2000) 0.94
Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet). Neurology (1987) 0.92
Hyperkinetic movement disorders misdiagnosed as tics in Gilles de la Tourette syndrome. Mov Disord (1998) 0.92
Complications of chronic levodopa therapy: long-term efficacy of drug holiday. Neurology (1981) 0.91
On the mechanism of sudden death in Moersch-Woltman syndrome. Neurology (1983) 0.91
Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord (2000) 0.91
Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm (Vienna) (1998) 0.90
Levodopa and presymptomatic detection of Huntington's disease--eight-year follow-up. N Engl J Med (1980) 0.89
Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol (2001) 0.89
Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology (1990) 0.89
Pharmacological therapy in progressive supranuclear palsy. Arch Neurol (1998) 0.88
Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol (1997) 0.88
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology (1985) 0.88
Drug-induced movement disorders. Neurol Clin (1998) 0.87
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord (1999) 0.87
Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol (2001) 0.87
Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes. Mov Disord (1990) 0.86
Neuropsychological dissociation between recognition familiarity and perceptual priming in visual long-term memory. Cortex (1998) 0.86
Bupropion in Parkinson's disease. Neurology (1984) 0.86
Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. Ann Intern Med (1978) 0.85
Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol (2001) 0.85
Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord (2000) 0.85
[Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. Rev Neurol (Paris) (2009) 0.85
5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. Eur J Pharmacol (1998) 0.84